Fennec Pharmaceuticals Stock Piotroski F Score

FENC Stock  USD 5.32  0.60  12.71%   
This module uses fundamental data of Fennec Pharmaceuticals to approximate its Piotroski F score. Fennec Pharmaceuticals F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Fennec Pharmaceuticals. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Fennec Pharmaceuticals financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Fennec Pharmaceuticals Altman Z Score, Fennec Pharmaceuticals Correlation, Fennec Pharmaceuticals Valuation, as well as analyze Fennec Pharmaceuticals Alpha and Beta and Fennec Pharmaceuticals Hype Analysis.
For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.
  
At present, Fennec Pharmaceuticals' Net Debt is projected to increase significantly based on the last few years of reporting. The current year's Long Term Debt is expected to grow to about 32.5 M, whereas Short Term Debt is forecasted to decline to about 18 K. At present, Fennec Pharmaceuticals' Inventory Turnover is projected to increase significantly based on the last few years of reporting. The current year's Days Of Inventory On Hand is expected to grow to 818.58, whereas Price To Sales Ratio is forecasted to decline to 13.33.
At this time, it appears that Fennec Pharmaceuticals' Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
3.0
Piotroski F Score - Frail
Current Return On Assets

Negative

Focus
Change in Return on Assets

Decreased

Focus
Cash Flow Return on Assets

Negative

Focus
Current Quality of Earnings (accrual)

Improving

Focus
Asset Turnover Growth

Increase

Focus
Current Ratio Change

Increase

Focus
Long Term Debt Over Assets Change

Higher Leverage

Focus
Change In Outstending Shares

Increase

Focus
Change in Gross Margin

No Change

Focus

Fennec Pharmaceuticals Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Fennec Pharmaceuticals is to make sure Fennec is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Fennec Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Fennec Pharmaceuticals' financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.830.7911
Sufficiently Up
Slightly volatile
Gross Profit Margin0.890.9408
Notably Down
Slightly volatile
Total Current Liabilities7.9 M7.6 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total32.5 M30.9 M
Sufficiently Up
Slightly volatile
Total Assets16.1 M26.9 M
Way Down
Slightly volatile
Total Current Assets28.2 M26.9 M
Sufficiently Up
Slightly volatile

Fennec Pharmaceuticals F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Fennec Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Fennec Pharmaceuticals in a much-optimized way.

About Fennec Pharmaceuticals Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value Per Share

(0.42)

At present, Fennec Pharmaceuticals' Book Value Per Share is projected to increase slightly based on the last few years of reporting.

Fennec Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Fennec Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Fennec Pharmaceuticals' managers, analysts, and investors.
Environmental
Governance
Social

About Fennec Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Fennec Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fennec Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fennec Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Fennec Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fennec Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fennec Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fennec Pharmaceuticals Stock:
Check out Fennec Pharmaceuticals Altman Z Score, Fennec Pharmaceuticals Correlation, Fennec Pharmaceuticals Valuation, as well as analyze Fennec Pharmaceuticals Alpha and Beta and Fennec Pharmaceuticals Hype Analysis.
For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fennec Pharmaceuticals. If investors know Fennec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fennec Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.04)
Revenue Per Share
1.814
Quarterly Revenue Growth
0.07
Return On Assets
0.027
Return On Equity
(10.06)
The market value of Fennec Pharmaceuticals is measured differently than its book value, which is the value of Fennec that is recorded on the company's balance sheet. Investors also form their own opinion of Fennec Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Fennec Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fennec Pharmaceuticals' market value can be influenced by many factors that don't directly affect Fennec Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fennec Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fennec Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fennec Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.